We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) is scheduled to report third-quarter 2018 results on Nov 1, after market close.
Last reported quarter, the company’s earnings per share surpassed the Zacks Consensus Estimate by 2.9%. The company delivered positive surprises in three of the trailing four quarters. However, a 74.6% miss in one of the four quarters led to an average miss of 12.6%.
Let’s take a look at how things are shaping up prior to this announcement.
Factors at Play
Tandem Diabetes is expected to see continued strength in the pump sales. Notably, pumps accounted for around 62% of total second-quarter 2018 sales. Tandem Diabetes shipped 800 renewals in the last quarter compared with 300 in the year-ago period.
Led by a growing number of ordering customers along with the increased sales of infusion set across the entire install base for the second quarter of 2018, Tandem Diabetes witnessed a 62% year-over-year rise in supplies sales.
These trends are expected to drive the top line in the yet-to-be reported quarter as well.
In August, Tandem Diabetes announced the launch of the t:slim X2 Insulin Pump with Basal-IQ predictive low glucose suspend technology in the United States.
In the same month, the company announced the online publication of results in the medical journal Diabetes Care from the PROLOG (PLGS for Reduction of Low Glucose) study of the t:slim X2 Insulin Pump with Basal-IQ Technology.
These new launches are expected to reflect on the top line in the third quarter of 2018.
Furthermore, Tandem Diabetes recently raised the sales guidance for 2018 on consistent strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select geographies.
Tandem Diabetes is consistently focusing on strengthening its global presence. In this regard, in the second quarter, the company entered into agreements with independent distributors in Australia, New Zealand, Italy, Scandinavia, South Africa, Spain and the United Kingdom. Also, the recently updated sales guidance for 2018 includes a projected $7-$8 million of sales, which had begun in August 2018, in select regions outside the United States.
As per the company’s recently-released preliminary sales result, third-quarter 2018 sales are projected in the range of $42-$44 million. This represents quarterly sales growth of 56-63% from around $27 million in the third quarter of 2017. Moreover, the preliminary sales figure includes $2 million of sales estimated in certain international regions.
The Zacks Consensus Estimate for third-quarter total revenues are projected at $42.7 million, indicating a rise of 58.3% from the prior-year quarter.
Here’s What Our Quantitative Model Predicts
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Tandem Diabeteshas a Zacks Rank #3 and an Earnings ESP of 0.00%, a combination that does not hint at an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for a loss of 34 cents per share reflects an improvement of 89% on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
Quidel Corporation (QDEL - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #3.
Myriad Genetics, Inc. (MYGN - Free Report) has an Earnings ESP of +9.1% and a Zacks Rank #3.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
Tandem Diabetes Care, Inc. (TNDM - Free Report) is scheduled to report third-quarter 2018 results on Nov 1, after market close.
Last reported quarter, the company’s earnings per share surpassed the Zacks Consensus Estimate by 2.9%. The company delivered positive surprises in three of the trailing four quarters. However, a 74.6% miss in one of the four quarters led to an average miss of 12.6%.
Let’s take a look at how things are shaping up prior to this announcement.
Factors at Play
Tandem Diabetes is expected to see continued strength in the pump sales. Notably, pumps accounted for around 62% of total second-quarter 2018 sales. Tandem Diabetes shipped 800 renewals in the last quarter compared with 300 in the year-ago period.
Led by a growing number of ordering customers along with the increased sales of infusion set across the entire install base for the second quarter of 2018, Tandem Diabetes witnessed a 62% year-over-year rise in supplies sales.
Tandem Diabetes Care, Inc. Price and EPS Surprise
Tandem Diabetes Care, Inc. Price and EPS Surprise | Tandem Diabetes Care, Inc. Quote
These trends are expected to drive the top line in the yet-to-be reported quarter as well.
In August, Tandem Diabetes announced the launch of the t:slim X2 Insulin Pump with Basal-IQ predictive low glucose suspend technology in the United States.
In the same month, the company announced the online publication of results in the medical journal Diabetes Care from the PROLOG (PLGS for Reduction of Low Glucose) study of the t:slim X2 Insulin Pump with Basal-IQ Technology.
These new launches are expected to reflect on the top line in the third quarter of 2018.
Furthermore, Tandem Diabetes recently raised the sales guidance for 2018 on consistent strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select geographies.
Tandem Diabetes is consistently focusing on strengthening its global presence. In this regard, in the second quarter, the company entered into agreements with independent distributors in Australia, New Zealand, Italy, Scandinavia, South Africa, Spain and the United Kingdom. Also, the recently updated sales guidance for 2018 includes a projected $7-$8 million of sales, which had begun in August 2018, in select regions outside the United States.
As per the company’s recently-released preliminary sales result, third-quarter 2018 sales are projected in the range of $42-$44 million. This represents quarterly sales growth of 56-63% from around $27 million in the third quarter of 2017. Moreover, the preliminary sales figure includes $2 million of sales estimated in certain international regions.
The Zacks Consensus Estimate for third-quarter total revenues are projected at $42.7 million, indicating a rise of 58.3% from the prior-year quarter.
Here’s What Our Quantitative Model Predicts
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Tandem Diabeteshas a Zacks Rank #3 and an Earnings ESP of 0.00%, a combination that does not hint at an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for a loss of 34 cents per share reflects an improvement of 89% on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
PerkinElmer has an Earnings ESP of +1.45% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Quidel Corporation (QDEL - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #3.
Myriad Genetics, Inc. (MYGN - Free Report) has an Earnings ESP of +9.1% and a Zacks Rank #3.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>